View Exam | PowerPak

1. The most significant non-modifiable risk factor for developing Alzheimer's disease is:

A. Education B. Family history C. Age D. Presence of the ApoE4 gene E. Unsure

2. The hallmark features of Alzheimer's disease are:

A. Cerebrovascular infarcts and Lewy bodies B. Neurofibrillary tangles and amyloid plaques C. Frontotemporal lobar degeneration and mass effect D. Tau plaques and cerebrovascular infarcts E. Unsure

3. The increasing prevalence of Alzheimer's disease is attributable to all of the following EXCEPT:

A. The aging baby boomer population in the United States B. The continuing extension of life expectancy C. The overall growth of the global population D. Increasing exposure to environmental toxins E. Unsure

4. A 77-year-old female is taking the following medications: lisinopril 10 mg once daily, atorvastatin 20 mg once daily, acetaminophen 500 mg every 4 to 6 hours as needed, venlafaxine 150 mg once daily, and oxybutynin 10 mg once daily. Which medication could worsen her symptoms of dementia?

A. Oxybutynin B. Atorvastatin C. Lisinopril D. Venlafaxine E. Unsure

5. Which drug is NOT an acetylcholinesterase inhibitor?

A. Donepezil B. Galantamine C. Rivastigmine D. Memantine E. Unsure

6. Use the following CASE STUDY to answer questions 6, 7 & 8:
A 62-year-old female was diagnosed with mild Alzheimer’s disease (AD) and started on rivastigmine tartrate. She has been taking 1.5 mg twice daily for the past 2 weeks. Now, her physician wants to increase her dose and prescribes 3 mg twice daily.

The patient's caregiver calls you and expresses concern that the patient is now experiencing gastrointestinal (GI) discomfort. Prior to this, she had tolerated the medication quite well. You tell the caregiver:

A. Nausea and diarrhea tend to occur during dosage adjustments and may subside as her body adjusts to the new dose. Taking rivastigmine with food may help. B. This is a sign that rivastigmine is not working correctly and the patient's therapy should be changed to memantine. C. Constipation is a common side effect of acetylcholinesterase inhibitors, and she should increase her dietary fiber. D. If she cannot tolerate one medication in this class, she will not tolerate any other. E. Unsure

7. Despite taking it as counseled, the patient's GI upset continues to be bothersome and she is resistant to taking the medication. Her dose was reduced back to 1.5 mg twice daily. Her mental status has remained stable (mild AD). What other option may be considered at this point?

A. Switching to the rivastigmine transdermal patch (9.5 mg/24 hours) B. Switching to the rivastigmine transdermal patch (4.6 mg/24 hours) C. Switching to memantine 10 mg twice daily, since the patient has failed the acetylcholinesterase inhibitor class D. Starting scopolamine 1.5 mg patch behind the ear to help control her GI symptoms E. Unsure

8. All of the following have been considered as potential objectives for drug development for targeting the amyloid pathway in Alzheimer's disease EXCEPT:

A. Passive immunizations against soluble Aβ using monoclonal antibodies B. Blocking gamma secretase C. Blocking beta secretase (BACE1 inhibitors) D. Blocking alpha secretase E. Unsure

9. Which of the following components of care is associated with the highest average annual per-person payment for Medicare beneficiaries aged 65 years and older with Alzheimer's disease?

A. Prescription medications B. Inpatient hospitalizations C. Home healthcare D. Hospice E. Unsure

10. Potential opportunities for healthcare savings with emerging drugs are:

A. Treatments that slow the rate of functional decline in Alzheimer's disease (AD) B. Treatments that reduce behavioral and psychological symptoms C. Treatments that delay the onset of AD D. All of the above E. Unsure

Evaluation Questions

11. How confident are you in your decision about treatment for your patient taking Rivastigmine tartrate in question 7?

A. Not at all confident B. Somewhat confident C. Confident D. Highly confident

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. The most significant non-modifiable risk factor for developing Alzheimer's disease is:

2. The hallmark features of Alzheimer's disease are:

3. The increasing prevalence of Alzheimer's disease is attributable to all of the following EXCEPT:

4. A 77-year-old female is taking the following medications: lisinopril 10 mg once daily, atorvastatin 20 mg once daily, acetaminophen 500 mg every 4 to 6 hours as needed, venlafaxine 150 mg once daily, and oxybutynin 10 mg once daily. Which medication could worsen her symptoms of dementia?

5. Which drug is NOT an acetylcholinesterase inhibitor?

7. Despite taking it as counseled, the patient's GI upset continues to be bothersome and she is resistant to taking the medication. Her dose was reduced back to 1.5 mg twice daily. Her mental status has remained stable (mild AD). What other option may be considered at this point?

8. All of the following have been considered as potential objectives for drug development for targeting the amyloid pathway in Alzheimer's disease EXCEPT:

9. Which of the following components of care is associated with the highest average annual per-person payment for Medicare beneficiaries aged 65 years and older with Alzheimer's disease?

10. Potential opportunities for healthcare savings with emerging drugs are:

Evaluation Questions

11. How confident are you in your decision about treatment for your patient taking Rivastigmine tartrate in question 7?

« Return to Activity

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. The most significant non-modifiable risk factor for developing Alzheimer's disease is:

2. The hallmark features of Alzheimer's disease are:

3. The increasing prevalence of Alzheimer's disease is attributable to all of the following EXCEPT:

4. A 77-year-old female is taking the following medications: lisinopril 10 mg once daily, atorvastatin 20 mg once daily, acetaminophen 500 mg every 4 to 6 hours as needed, venlafaxine 150 mg once daily, and oxybutynin 10 mg once daily. Which medication could worsen her symptoms of dementia?

5. Which drug is NOT an acetylcholinesterase inhibitor?

7. Despite taking it as counseled, the patient's GI upset continues to be bothersome and she is resistant to taking the medication. Her dose was reduced back to 1.5 mg twice daily. Her mental status has remained stable (mild AD). What other option may be considered at this point?

8. All of the following have been considered as potential objectives for drug development for targeting the amyloid pathway in Alzheimer's disease EXCEPT:

9. Which of the following components of care is associated with the highest average annual per-person payment for Medicare beneficiaries aged 65 years and older with Alzheimer's disease?

10. Potential opportunities for healthcare savings with emerging drugs are:

Evaluation Questions

11. How confident are you in your decision about treatment for your patient taking Rivastigmine tartrate in question 7?

« Return to Activity

Customers who Purchased
this Activity also Purchased